eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Metabolic Diseases

Phenylketonuria: Follow-up

Author: Georgianne L Arnold, MD, Director of Inherited Metabolic Disorders Clinic, Department of Pediatrics and Genetics, Associate Professor, University of Rochester School of Medicine and Dentistry
Contributor Information and Disclosures

Updated: Feb 13, 2009

Follow-up

Inpatient & Outpatient Medications

  • Patients with phenylketonuria should avoid aspartame (an artificial sweetener). Aspartame is widely used in medicines, vitamins, beverages, and other substances.

Complications

  • Subtle attention and performance deficits in organization and planning persist in treated patients. These deficits are related to phenylalanine levels and may interfere with academic achievement.
  • A few patients experience psychological problems, including poor self-esteem. Agoraphobia and more severe problems have been described, especially in women who have discontinued the diet. Because phenylalanine competes with tryptophan (the precursor of serotonin) for entry into the brain, psychological symptoms may have a biological basis and improved dietary control is recommended.

Prognosis

  • Prognosis for normal intelligence is excellent with dietary treatment. However, school functioning can be mildly impaired in some children, particularly when dietary control is poor.

Patient Education

  • Teach parents how to administer the diet at home and involve all caregivers as well.
  • Children should begin involvement in their dietary planning as soon as they are developmentally ready.

Miscellaneous

Medicolegal Pitfalls

  • Failure to provide adequate phenylalanine to patients with phenylketonuria (PKU), resulting in deficiency of this essential amino acid (eg, beginning a phenylalanine-free formula in a neonate without adding a source of phenylalanine)
  • Failure to consider diagnosis in a child who is developmentally abnormal even if screening was normal
  • Failure to perform testing for biopterin defects
  • Failure to provide adequate energy intake, essential amino acids, vitamins, and minerals
  • Failure to monitor for common nutritional deficiencies
  • Failure to recognize that screening may have been performed too soon (ie, before 12-24 h of life, depending on local standards), leading to in a false-negative result

Special Concerns

  • Birth defects, microcephaly, and mental retardation are common in infants of mothers with phenylketonuria if the mother's phenylalanine levels are not controlled during pregnancy.
  • Women must maintain phenylalanine levels from 2-6 mg/dL during pregnancy.
 


More on Phenylketonuria

Overview: Phenylketonuria
Differential Diagnoses & Workup: Phenylketonuria
Treatment & Medication: Phenylketonuria
Follow-up: Phenylketonuria
Multimedia: Phenylketonuria
References
[ CLOSE WINDOW ]

References

  1. Yannicelli S, Ryan A. Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. J Inherit Metab Dis. 1995;18(2):131-4. [Medline].

  2. Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis. Oct 2007;30(5):700-7. [Medline].

  3. Schindeler S, Ghosh-Jerath S, Thompson S, et al. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab. May 2007;91(1):48-54. [Medline].

  4. Sarkissian CN, Gamez A, Wang L, et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci U S A. Dec 30 2008;105(52):20894-9. [Medline].

  5. Anderson PJ, Wood SF, Francis DE, et al. Neuropsychological function in children with early-treated phenylketonuria: impact of white matter abnormalities. Dev Med Child Neurol. 2004;46:230-8. [Medline].

  6. Bekhof J, van Spronsen FJ, Crone MR, et al. Influence of knowledge of the disease on metabolic control in phenylketonuria. Eur J Pediatr. Jun 2003;162(6):440-2. [Medline].

  7. Brumm VL, Azen C, Moats RA, et al. Neuropsyhchological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J Inherit Metab Dis. 2004;27:549-66. [Medline].

  8. Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev. 1997;62(4):i-v, 1-208. [Medline].

  9. Fisch RO, Matalon R, Weisberg S, Michals K. Phenylketonuria: current dietary treatment practices in the United States and Canada. J Am Coll Nutr. Apr 1997;16(2):147-51. [Medline].

  10. Matalon R, Michals-Matalon K, Koch R, et al. Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Mol Genet Metab. Dec 2005;86 Suppl 1:S17-21. [Medline].

  11. Scriver CR, Kaufman S, Eisensmith RC. The hyperphenylalaninemias. In: The Metabolic and Molecular Bases of Inherited Disease. Vol 1. 1995:1015-76.

  12. Smith I, Beasley MG, Ades AE. Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch Dis Child. Mar 1991;66(3):311-6. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

phenylketonuria, PKU, Folling disease, Folling's disease, hyperphenylalaninemia, phenylalanine hydroxylase deficiency, mental retardation, tetrahydrobiopterin deficiency, malignant phenylketonuria, agoraphobia, developmental delay, mousy odor, seizures, self-mutilation, behavioral disorder

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Georgianne L Arnold, MD, Director of Inherited Metabolic Disorders Clinic, Department of Pediatrics and Genetics, Associate Professor, University of Rochester School of Medicine and Dentistry
Georgianne L Arnold, MD is a member of the following medical societies: American College of Medical Genetics, American Society of Human Genetics, Society for Inherited Metabolic Disorders, and Society for the Study of Inborn Errors of Metabolism
Disclosure: Biomarin Grant/research funds clinical trial

Medical Editor

Christian J Renner, MD, Consulting Staff, Department of Pediatrics, University Hospital for Children and Adolescents, Erlangen, Germany
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Robert Anthony Saul, MD, Clinical Professor, Department of Pediatrics, University of South Carolina; Senior Clinical Geneticist, Greenwood Genetic Center
Robert Anthony Saul, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, and American College of Physician Executives
Disclosure: Nothing to disclose.

CME Editor

Paul D Petry, DO, FACOP, FAAP, Consulting Staff, Freeman Pediatric Care, Freeman Health System
Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association
Disclosure: Nothing to disclose.

Chief Editor

Bruce Buehler, MD, Professor, Department of Pediatrics, Pathology and Microbiology, Executive Director, Hattie B Munroe Center for Human Genetics and Rehabilitation, University of Nebraska Medical Center
Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.